专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10633639B2 Chimeras of 有权
公开(公告)号：US10633639B2
公开(公告)日：2020-04-28
申请号：US14894484
申请日：2014-05-26
申请人： INMUNOVA S.A. , CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS
发明人： Fernando Alberto Goldbaum , Vanesa Zylberman , Patricio Oliver Craig , Giselle Ghersi , Marina Sandra Palermo , Maria Pilar Mejias , Leticia Veronica Bentancor
IPC分类号： C12N9/10 , A61K39/108 , C07K16/12 , C07K16/18 , A61K39/02 , A61K38/45 , C07K14/245 , C07K16/40 , A61K39/00 , A61K38/00
CPC分类号： C12N9/1085 , A61K38/45 , A61K39/0258 , A61K39/098 , C07K14/245 , C07K16/1232 , C07K16/18 , C07K16/40 , A61K38/00 , A61K2039/505 , A61K2039/523 , A61K2039/545 , A61K2039/55505 , A61K2039/55566 , A61K2039/575 , A61K2039/6037 , A61K2039/6068 , C07K2317/20 , C07K2317/22 , C07K2317/31 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2319/55 , C12Y205/01078 , Y02A50/474
摘要： Chimeric polypeptides useful as immunogens for inducing protective immune responses and neutralizing antibodies against Shiga toxin (Stx) in mammals. More specifically, chimeric polypeptides having a monomer of the homopentameric B subunit of the Shiga 2 toxin fused to the N-terminus of a monomer of Brucella lumazine synthase, and to oligomeric protein complexes formed from said chimeric polypeptides. Polynucleotides and vectors encoding said chimeric polypeptides, transgenic cells having said polynucleotides and vectors, pharmaceutical compositions, such as a vaccine, having said chimeric polypeptides and chimeric polynucleotides, antibodies which bind to the chimeric polypeptides, a method for obtaining antibodies which bind specifically to the subunit B of the Shiga 2 toxin and methods of lowering the bacterial load of enterohemorrhagic Escherichia coli in mammals, which can be used for prevention of inter alia, hemolytic-ureic syndrome (HUS), are also provided.

2. 发明授权

US09517262B2 Vaccine injection, preparation method and use thereof 有权
标题翻译：疫苗注射，其制备方法和用途
公开(公告)号：US09517262B2
公开(公告)日：2016-12-13
申请号：US14004786
申请日：2011-04-08
申请人： Jiabo Wang , Xiaohe Xiao , Zhewei Wang , Cheng Jin , Qi Li
发明人： Jiabo Wang , Xiaohe Xiao , Zhewei Wang , Cheng Jin , Qi Li
IPC分类号： A61K39/00 , A61K39/39 , A61K39/29 , A61K39/07 , A61K39/08 , A61K39/02 , A61K39/112 , A61K39/145 , A61K39/165 , A61K39/20 , A61K39/05 , A61K39/12
CPC分类号： A61K39/29 , A61K39/00 , A61K39/0208 , A61K39/0275 , A61K39/0291 , A61K39/05 , A61K39/07 , A61K39/08 , A61K39/098 , A61K39/099 , A61K39/12 , A61K39/145 , A61K39/165 , A61K39/20 , A61K39/39 , A61K2039/54 , A61K2039/55505 , A61K2039/55588 , C12N2760/18434 , C12N2770/24134 , C12N2770/32434 , Y02A50/39 , Y02A50/407 , Y02A50/484
摘要： The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.
摘要翻译：本发明提供疫苗注射液，其质量比为1:0.5-1:10的疫苗和中药佐剂，或者以1：0.5-1：10的质量比计的疫苗，中药辅剂和铝佐剂， 0.5：2.5-1：10：20。疫苗注射为粉末形式，粉末的尺寸为10至120微米。本发明的疫苗注射特别适用于无针注射技术。本发明还提供了疫苗注射的制备方法。

3. 发明授权

US09138468B2 Modified pathogens for use as vaccines 有权
标题翻译：用作疫苗的改良病原体
公开(公告)号：US09138468B2
公开(公告)日：2015-09-22
申请号：US14306815
申请日：2014-06-17
申请人： University of Massachusetts
发明人： Egil Lien , Jon D. Goguen
IPC分类号： A61K48/00 , A01N63/00 , A61K39/02 , C12Q1/02 , G01N33/569 , A61K39/118 , A61K39/00
CPC分类号： A61K39/0291 , A61K39/0208 , A61K39/025 , A61K39/098 , A61K39/118 , A61K2039/55572 , C12Q1/025 , G01N33/56911 , Y02A50/407 , Y02A50/478
摘要： Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., Yersinia pestis expressing LpxL. Such modified microorganisms may be used as vaccines for protection against an infection by the unmodified microorganism. They may also be used as delivery vehicles of one or more heterologous antigens, e.g., antigens from pathogens or those associated with a hyperproliferative eukaryotic cell.
摘要翻译：这里描述的是相对于未修饰的微生物进行修饰以使得它们具有增强的真核生物免疫系统识别能力的微生物。微生物可以是已被修饰以产生高效力脂多糖的革兰氏阴性细菌，例如表达LpxL的耶尔森氏菌。这种修饰的微生物可以用作防止未经修饰的微生物感染的疫苗。它们还可以用作一种或多种异源抗原的递送载体，例如来自病原体的抗原或与过度增殖的真核细胞相关的抗原。

4. 发明申请

US20150202283A1 METHOD FOR ELICITING IN INFANTS AN IMMUNE RESPONSE AGAINST RSV AND B. PERTUSSIS 审中-公开
标题翻译：免疫应答对RSV和B的免疫反应的方法
公开(公告)号：US20150202283A1
公开(公告)日：2015-07-23
申请号：US14419990
申请日：2013-08-05
申请人： GLAXOSMITHKLINE BIOLOGICALS, S.A.
发明人： Ann-Muriel Steff , Stephane T. Temmerman , Jean-Francois Toussaint
IPC分类号： A61K39/155 , A61K39/02 , A61K39/39 , C12N7/00
CPC分类号： A61K39/155 , A61K39/05 , A61K39/08 , A61K39/098 , A61K39/099 , A61K39/12 , A61K39/145 , A61K39/39 , A61K45/06 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/70 , C12N7/00 , C12N2760/18534
摘要： This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) and Bordetella pertussis through maternal immunization using recombinant respiratory syncytial virus (RSV) and B. pertussis antigens to reduce the incidence or severity of RSV and pertussis infection in young infants.
摘要翻译：本公开提供了通过使用重组呼吸道合胞病毒（RSV）和百日咳杆菌抗原的母体免疫来保护婴儿免受呼吸道合胞病毒（RSV）和百日咳博德特氏菌引起的疾病的方法，以减少幼儿中RSV和百日咳感染的发生率或严重性。

5. 发明授权

US08846078B2 Brucellosis DNA vaccine 有权
标题翻译：布鲁氏杆菌DNA疫苗
公开(公告)号：US08846078B2
公开(公告)日：2014-09-30
申请号：US11688519
申请日：2007-03-20
申请人： Nicola Commander , Stephen Spencer
发明人： Nicola Commander , Stephen Spencer
IPC分类号： A61K9/127 , A61K39/02 , A61K45/00 , G01N33/569 , A61K48/00 , A61K39/00
CPC分类号： G01N33/56911 , A61K9/127 , A61K39/098 , A61K48/00 , A61K2039/53 , A61K2039/55555 , A61K2039/57 , A61K2039/6018 , G01N2333/23 , G01N2469/20
摘要： Brucellosis is a disease caused by facultative intracellular bacteria of the monospecific genus Brucella melitensis. The invention in one aspect is an immunogenic nucleic acid composition comprising DNA encoding Brucella melitensis Invasion Protein B, a polypeptide with at least 95% identity thereto, or an immunologically active fragment of either of these, and an adjuvant. In another aspect, the invention is a DNA vaccine composition comprising a plasmid vector having DNA encoding a polypeptide as recited above, in which said plasmid vector is adsorbed to a liposome. Other aspects of the invention include methods of inducing an enhanced immune response to Brucella infection in an animal, methods for the differential diagnosis in an animal of brucellosis and vaccination by an immunogenic nucleic acid composition having DNA encoding any of the above-recited polypeptides, and a kit for conducting said differential diagnosis methods.
摘要翻译：布鲁氏菌病是由单性Brucella melitensis的兼性细胞内细菌引起的疾病。本发明的一个方面是免疫原性核酸组合物，其包含编码布鲁氏菌侵袭蛋白B的DNA，与其至少95％同一性的多肽，或其任一种的免疫活性片段和佐剂。另一方面，本发明是一种DNA疫苗组合物，其包含具有编码上述多肽的DNA的质粒载体，其中所述质粒载体被吸附到脂质体上。本发明的其它方面包括在动物中诱导对布鲁氏杆菌感染的增强的免疫应答的方法，布鲁氏菌病动物鉴别诊断的方法和具有编码任何上述多肽的DNA的免疫原性核酸组合物的接种，以及用于进行所述鉴别诊断方法的试剂盒。

6. 发明申请

US20140037680A1 NOVEL METHOD 审中-公开
标题翻译：新方法
公开(公告)号：US20140037680A1
公开(公告)日：2014-02-06
申请号：US13835829
申请日：2013-03-15
申请人： GLAXOSMITHKLINE BIOLOGICALS, S.A.
发明人： Ann-Muriel STEFF , Jean-Francios TOUSSAINT
IPC分类号： A61K39/155 , A61K39/08 , A61K39/02 , A61K39/05 , A61K45/06 , A61K39/145
CPC分类号： A61K39/155 , A61K39/05 , A61K39/08 , A61K39/098 , A61K39/099 , A61K39/12 , A61K39/145 , A61K39/39 , A61K45/06 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/70 , C12N7/00 , C12N2760/18534
摘要： This disclosure provides methods for protecting infants against disease caused by respiratory syncytial virus (RSV) through maternal immunization using recombinant respiratory syncytial virus (RSV) antigens to reduce the incidence or severity of RSV infection in young infants.
摘要翻译：本公开提供了通过使用重组呼吸道合胞病毒（RSV）抗原通过母体免疫来保护婴儿免受呼吸道合胞病毒（RSV）引起的疾病的方法，以减少幼儿RSV感染的发生率或严重性。

7. 发明申请

US20120183576A1 MODIFIED GRAM-NEGATIVE BACTERIA FOR USE AS VACCINES 有权
标题翻译：用作疫苗的改良的GRAM-Negative BACTERIA
公开(公告)号：US20120183576A1
公开(公告)日：2012-07-19
申请号：US13496007
申请日：2010-09-21
申请人： Jean-Pierre Gorvel , Vilma Arce Gorvel , Maite Iriarte , Ignacio Moriyon , Raquel Conde-Alvarez
发明人： Jean-Pierre Gorvel , Vilma Arce Gorvel , Maite Iriarte , Ignacio Moriyon , Raquel Conde-Alvarez
IPC分类号： A61K39/10 , A61K39/02 , A61P31/04 , A61K31/739 , A61K39/39 , A61P37/04 , C12N1/20 , C08B37/00
CPC分类号： A61K39/39 , A61K39/098 , A61K2039/522 , A61K2039/552
摘要： The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host.
摘要翻译：本发明涉及携带编码参与合成所述革兰氏阴性菌的LPS核心的糖基转移酶的灭活基因的革兰氏阴性细菌，其中所述灭活基因导致具有修饰核心的LPS的合成。这些菌株具有减毒的毒力，但诱导足够的体液免疫以确保宿主的疫苗接种。

8. 发明申请

US20120142555A1 Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis 有权
标题翻译：结核分枝杆菌免疫显性抗原的组成和方法
公开(公告)号：US20120142555A1
公开(公告)日：2012-06-07
申请号：US13396213
申请日：2012-02-14
申请人： Philip Felgner , Xiaowu Liang , Maria Laura Gennaro
发明人： Philip Felgner , Xiaowu Liang , Maria Laura Gennaro
IPC分类号： C40B30/04
CPC分类号： C12N15/1068 , A61K39/015 , A61K39/0208 , A61K39/0225 , A61K39/04 , A61K39/098 , A61K39/118 , A61K39/12 , A61K39/245 , A61K39/285 , A61K39/385 , A61K2039/60 , C07K14/005 , C12N2710/16621 , C12N2710/16622 , C12N2710/16634 , C12N2710/24122 , C12N2710/24134 , G01N33/566 , G01N33/56911 , G01N33/56916 , G01N33/56927 , G01N33/5695 , G01N33/56983 , G01N33/56994 , G01N33/6854 , G01N2333/35 , G01N2469/20 , Y02A50/401 , Y02A50/412
摘要： Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
摘要翻译：研究的组合物，装置和方法被描绘为来自病原体结核分枝杆菌的各种抗原及其在疫苗，治疗剂和各种诊断测试中的用途。在特别优选的方面，抗原是免疫显性的，并且相对于感染病原体的群体的血清具有定量和已知的相对反应性，和/或具有与疾病参数的已知关联。

9. 发明申请

US20110200667A1 VETERINARY PHARMACEUTICAL FORMULACION THAT COMPRISES AN RNA RECOMBINANT PARTICLE THAT ENCODES FOR A CU/ZN SUPEROXIDE DISMUTASE PROTEIN OF RUMINANT PATHOGENIC BACTERIA AND AT LEAST ONE RNA ALPHAVIRUS BELONGING TO THE SEMLIKI FOREST VIRUS FAMILY 审中-公开
标题翻译：包含RNA重组颗粒的兽用药物制剂，其编码针对致病性细菌性细菌的CU / ZN超氧化物歧化酶蛋白和至少一种与SEMLIKI森林病毒家族相关的一种RNA ALPHAVIRUS
公开(公告)号：US20110200667A1
公开(公告)日：2011-08-18
申请号：US13057620
申请日：2009-08-07
申请人： Angel Oñate Contreras , Edilia Andrews Garcia , Gabriel Donoso Ñanculao
发明人： Angel Oñate Contreras , Edilia Andrews Garcia , Gabriel Donoso Ñanculao
IPC分类号： A61K9/127 , A61K31/7088 , A61P31/04
CPC分类号： A61K39/098 , A61K38/00 , A61K2039/5256 , A61K2039/53 , A61K2039/552 , A61K2039/55555 , C12N9/0089 , C12N2770/36143
摘要： The technology is a veterinary pharmaceutical formulation of two vaccines, one from an RNA viral vector system constituted by an RNA recombinant particle that codifies for a Cu/Zn superoxide dismutase protein of Brucella abortus, and the other based on naked RNA constituted by a recombinant molecule of naked RNA that carries a sequence for the synthesis of at least one recombinant Cu/Zn superoxide dismutase protein of Brucella abortus and some Semliki Forest virus genes. An expression system based on the Semliki Forest virus and a use of this system, in addition to a method for the preparation of the pharmaceutical formulations.
摘要翻译：该技术是两种疫苗的兽用药物制剂，一种来自由编码布鲁氏菌流产的Cu / Zn超氧化物歧化酶蛋白的RNA重组颗粒构成的RNA病毒载体系统，另一种基于由重组分子构成的裸RNA 的裸RNA携带用于合成至少一种流产布鲁杆菌的重组Cu / Zn超氧化物歧化酶蛋白和一些Semliki Forest病毒基因的序列。除了制备药物制剂的方法之外，还基于Semliki Forest病毒的表达系统和该系统的使用。

10. 发明授权

US07541447B2 Process for the preparation of an improved Brucella strain plasmid to develop the strain and the vaccine comprising the said strain 有权
标题翻译：用于制备改良的布鲁杆菌菌株质粒以开发菌株和包含所述菌株的疫苗的方法
公开(公告)号：US07541447B2
公开(公告)日：2009-06-02
申请号：US10978244
申请日：2004-10-28
申请人： Juan Esteban Ugalde , Diego José Comerci , Rodolfo Augusto Ugalde , Vito G. Del Vecchio
发明人： Juan Esteban Ugalde , Diego José Comerci , Rodolfo Augusto Ugalde , Vito G. Del Vecchio
IPC分类号： C07H21/02 , C07H21/04 , A61K49/00 , A01N63/00
CPC分类号： A61K39/098 , A61K2039/522 , A61K2039/523 , C12N1/36 , C12N9/90
摘要： A Brucella bacterium is modified by partial or complete deletion of the pgm gene, rendering the bacterium incapable of synthesizing a key enzyme in the metabolism of bacterial sugars. A live vaccine for immunization, prophylaxis or treatment of brucellosis comprises such a bacterium, either lyophilized or in a pharmaceutical vehicle. Nucleotide sequence fragments having the aforementioned deletion are disclosed, with methods for making them.
摘要翻译：通过部分或完全删除pgm基因修饰布鲁杆菌细菌，使细菌不能合成细菌糖代谢中的关键酶。用于免疫，预防或治疗布鲁氏菌病的活疫苗包括冻干的或在药物载体中的这种细菌。公开了具有上述缺失的核苷酸序列片段及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式